Transjugular Intrahepatic Portosystemic Shunt Is Associated With Better Waitlist Management of Liver Transplant Candidates With Hepatocellular Carcinoma
Transplant International · 2024
DOI: 10.3389/ti.2024.12781 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant International, 2024. Verfasst von Sofia El Hajji und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Abdominal Surgery, Department of Surgery, Geneva University Hospitals, Geneva, Switzerland. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Transplantation, Waiting Lists, Liver Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Transjugular intrahepatic portosystemic shunt (TIPS) reduces portal hypertension complications. Its impact on hepatocellular carcinoma (HCC) remains unclear. We evaluated 42,843 liver transplant candidates with HCC from the Scientific Registry of Transplant Recipients (2002–2022). 4,484 patients with and without TIPS were propensity score-matched 1:3. Analysing wait-list changes in total tumor volume, HCC count, and alpha-fetoprotein levels, and assessing survival from listing and transplantation; TIPS correlated with a decreased nodule count (−0.24 vs. 0.04, p = 0.028) over a median wait period of 284 days (IQR 195–493) and better overall survival from listing (95.6% vs. 91.5% at 1 year, p < 0.0001). It was not associated with changes in tumor volume (0.28 vs. 0.11 cm³/month, p = 0.58) and AFP (14.37 vs. 20.67 ng/mL, p = 0.42). Post-transplant survival rates (91.8% vs. 91.7% at 1 year, p = 0.25) and HCC recurrence (5.1% vs. 5.9% at 5 years, p = 0.14) were similar, with a median follow-up of 4.98 years (IQR 2.5–8.08). While TIPS was associated with a reduced nodule count and improved waitlist survival, it did not significantly impact HCC growth or aggressiveness. These findings suggest potential benefits of TIPS in HCC management, but further studies need to confirm TIPS safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Abdominal Surgery, Department of Surgery, Geneva University Hospitals, Geneva, Switzerland.
- Laboratory of Transplantation and Hepatology, University of Geneva, Geneva, Switzerland.
- Division of Transplantation, Department of Surgery, Geneva University Hospitals, Geneva, Switzerland.
Zitieren
APA
El Hajji, S., Lacotte, S., Moeckli, B., Cauchy, F., Compagnon, P., & Toso, C. (2024). Transjugular Intrahepatic Portosystemic Shunt Is Associated With Better Waitlist Management of Liver Transplant Candidates With Hepatocellular Carcinoma. Transplant International. https://doi.org/10.3389/ti.2024.12781
Vancouver
El Hajji S, Lacotte S, Moeckli B, Cauchy F, Compagnon P, Toso C. Transjugular Intrahepatic Portosystemic Shunt Is Associated With Better Waitlist Management of Liver Transplant Candidates With Hepatocellular Carcinoma. Transplant International. 2024. doi:10.3389/ti.2024.12781
BibTeX
@article{ElHajji2024,
author = {El Hajji, Sofia and Lacotte, Stéphanie and Moeckli, Beat and Cauchy, François and Compagnon, Philippe and Toso, Christian},
title = {Transjugular Intrahepatic Portosystemic Shunt Is Associated With Better Waitlist Management of Liver Transplant Candidates With Hepatocellular Carcinoma},
journal = {Transplant International},
year = {2024},
doi = {10.3389/ti.2024.12781}
}
EUVIMED